WOBURN, Mass. , Nov. 12, 2020 (GLOBE NEWSWIRE) — Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members of its senior management team will host investor meetings at the at the SVB